Literature DB >> 31605538

Chemical imaging of evolving amyloid plaque pathology and associated Aβ peptide aggregation in a transgenic mouse model of Alzheimer's disease.

Wojciech Michno1, Patrick Wehrli1, Silvio R Meier2, Dag Sehlin2, Stina Syvänen2, Henrik Zetterberg1,3,4,5, Kaj Blennow1,3, Jörg Hanrieder1,5.   

Abstract

One of the major hallmarks of Alzheimer's disease (AD) pathology is the formation of extracellular amyloid β (Aβ) plaques. While Aβ has been suggested to be critical in inducing and, potentially, driving the disease, the molecular basis of AD pathogenesis is still under debate. Extracellular Aβ plaque pathology manifests itself upon aggregation of distinct Aβ peptides, resulting in morphologically different plaque morphotypes, including mainly diffuse and cored senile plaques. As plaque pathology precipitates long before any clinical symptoms occur, targeting the Aβ aggregation processes provides a promising target for early interventions. However, the chain of events of when, where and what Aβ species aggregate and form plaques remains unclear. The aim of this study was to investigate the potential of matrix-assisted laser desorption/ionization imaging mass spectrometry as a tool to study the evolving pathology in transgenic mouse models for AD. To that end, we used an emerging, chemical imaging modality - matrix-assisted laser desorption/ionization imaging mass spectrometry - that allows for delineating Aβ aggregation with specificity at the single plaque level. We identified that plaque formation occurs first in cortical regions and that these younger plaques contain higher levels of 42 amino acid-long Aβ (Aβ1-42). Plaque maturation was found to be characterized by a relative increase in deposition of Aβ1-40, which was associated with the appearance of a cored morphology for those plaques. Finally, other C-terminally truncated Aβ species (Aβ1-38 and Aβ1-39) exhibited a similar aggregation pattern as Aβ1-40, suggesting that these species have similar aggregation characteristics. These results suggest that initial plaque formation is seeded by Aβ1-42; a process that is followed by plaque maturation upon deposition of Aβ1-40 as well as deposition of other C-terminally modified Aβ species.
© 2019 International Society for Neurochemistry.

Entities:  

Keywords:  Alzheimer’s disease; MALDI imaging; beta-amyloid; plaque pathology; transgenics

Mesh:

Substances:

Year:  2019        PMID: 31605538     DOI: 10.1111/jnc.14888

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  4 in total

1.  The Citrus Flavonoid Hesperetin Encounters Diabetes-Mediated Alzheimer-Type Neuropathologic Changes through Relieving Advanced Glycation End-Products Inducing Endoplasmic Reticulum Stress.

Authors:  Mei-Chou Lai; Wayne-Young Liu; Shorong-Shii Liou; I-Min Liu
Journal:  Nutrients       Date:  2022-02-10       Impact factor: 5.717

2.  Surface Modification of Curcumin Microemulsions by Coupling of KLVFF Peptide: A Prototype for Targeted Bifunctional Microemulsions.

Authors:  Rungsinee Phongpradist; Wisanu Thongchai; Kriangkrai Thongkorn; Suree Lekawanvijit; Chuda Chittasupho
Journal:  Polymers (Basel)       Date:  2022-01-22       Impact factor: 4.329

Review 3.  PET Imaging in Preclinical Anti-Aβ Drug Development.

Authors:  Stina Syvänen; Silvio R Meier; Sahar Roshanbin; Mengfei Xiong; Rebecca Faresjö; Tobias Gustavsson; Gillian Bonvicini; Eva Schlein; Ximena Aguilar; Ulrika Julku; Jonas Eriksson; Dag Sehlin
Journal:  Pharm Res       Date:  2022-05-02       Impact factor: 4.580

4.  11C-PiB and 124I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention.

Authors:  Silvio R Meier; Dag Sehlin; Sahar Roshanbin; Victoria Lim Falk; Takashi Saito; Takaomi C Saido; Ulf Neumann; Johanna Rokka; Jonas Eriksson; Stina Syvänen
Journal:  J Nucl Med       Date:  2021-06-04       Impact factor: 10.057

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.